Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2026-10-08 Purchase | 2026-10-09 08:01 am | AgomAb Therapeutics NV | AGMB | Epstein David R Director | 5,000 | $8.9 | $44,500 | 15,000 (Direct) | View |
| 2026-10-05 Purchase | 2026-10-07 08:57 am | AgomAb Therapeutics NV | AGMB | Epstein David R Director | 10,000 | $8.635 | $86,350 | 10,000 (Direct) | View |
| 2026-10-06 Purchase | 2026-10-07 08:47 am | AgomAb Therapeutics NV | AGMB | Kemula Pierre Thadee Victor Chief Financial Officer | 10,000 | $8.594 | $85,940 | 10,000 (Direct) | View |
| 2026-10-05 Purchase | 2026-10-07 08:06 am | AgomAb Therapeutics NV | AGMB | Knotnerus Tim Jasper Chief Executive Officer | 11,000 | $8.58 | $94,380 | 56,217 (Indirect Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2026-09-11 Option Award | 2026-09-15 4:06 pm | N/A 2036-01-15 | AgomAb Therapeutics NV | AGMB | Garcia Marino Director | 57,482 | $0 | 57,482 (Direct) | View |
| 2026-09-11 Option Award | 2026-09-15 4:06 pm | N/A 2036-01-15 | AgomAb Therapeutics NV | AGMB | Patel Naimish Director | 56,328 | $0 | 56,328 (Direct) | View |
Ownership | 2026-03-18 4:01 pm | N/A 2034-07-08 | Agomab Therapeutics NV | AGMB | Epstein David R Director | 0 | $0 | 1,026,809 (Direct) | View |
Ownership | 2026-03-18 4:01 pm | N/A N/A | Agomab Therapeutics NV | AGMB | Knotnerus Tim Jasper Chief Executive Officer | 0 | $0 | 2,128,092 (Direct) | View |
Ownership | 2026-03-18 4:01 pm | N/A 2034-11-04 | Agomab Therapeutics NV | AGMB | Bond Colin Michael Director | 0 | $0 | 151,407 (Direct) | View |
Ownership | 2026-03-18 4:01 pm | N/A 2036-01-15 | Agomab Therapeutics NV | AGMB | Hammer Ohad Director | 0 | $0 | 27,921 (Direct) | View |
Ownership | 2026-03-18 4:01 pm | N/A 2034-07-08 | Agomab Therapeutics NV | AGMB | Kemula Pierre Thadee Victor Chief Financial Officer | 0 | $0 | 583,020 (Direct) | View |
Ownership | 2026-03-18 4:01 pm | N/A 2033-10-10 | Agomab Therapeutics NV | AGMB | Jahreis Angelika Martha Director | 0 | $0 | 154,992 (Direct) | View |
Ownership | 2026-03-18 4:01 pm | N/A 2031-03-05 | Agomab Therapeutics NV | AGMB | van der Horst Paul Henryk Chief Business Officer | 0 | $0 | 612,556 (Direct) | View |
Ownership | 2026-03-18 4:01 pm | N/A 2036-01-15 | Agomab Therapeutics NV | AGMB | Verduyn-van Weegen Felice Isabel Director | 0 | $0 | 32,700 (Direct) | View |
Ownership | 2026-03-18 4:01 pm | N/A 2031-03-05 | Agomab Therapeutics NV | AGMB | Borderias Andrea Saez Chief Development Officer | 0 | $0 | 586,154 (Direct) | View |
Ownership | 2026-03-18 4:01 pm | N/A 2031-03-05 | Agomab Therapeutics NV | AGMB | Lefever Ellen General Counsel | 0 | $0 | 457,304 (Direct) | View |
Ownership | 2026-03-18 4:01 pm | N/A 2029-03-14 | Agomab Therapeutics NV | AGMB | Wiesel Philippe Constantin Chief Medical Officer | 0 | $0 | 627,775 (Direct) | View |